Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | ME2 | P23368 | 1/20 | 0.51 |
| ▸ | ME1 | P48163 | 1/20 | 0.51 |
| ▸ | ME3 | Q16798 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GPR183 | P32249 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399171 | 1.00 | LMNA (0.56) | LMNARAB9AMEN1KMT2AHTT | |
| SCHEMBL1399054 | 0.87 | LMNA (0.53) | LMNARAB9AMEN1KMT2AHTT | |
| SCHEMBL1399052 | 0.87 | LMNA (0.53) | LMNARAB9AMEN1KMT2AHTT | |
| SCHEMBL1399089 | 0.82 | KDM4E (0.57) | LMNARAB9AMEN1KMT2AGAA | |
| SCHEMBL1399090 | 0.82 | KDM4E (0.57) | LMNARAB9AMEN1KMT2AGAA | |
| SCHEMBL1399092 | 0.81 | MAPT (0.61) | LMNARAB9AMEN1KMT2AHTT | |
| SCHEMBL1399095 | 0.81 | MAPT (0.61) | LMNARAB9AMEN1KMT2AHTT | |
| SCHEMBL1399117 | 0.79 | C3AR1 (0.49) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL1399116 | 0.79 | C3AR1 (0.49) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL1399106 | 0.78 | C3AR1 (0.51) | MEN1KMT2AHTTALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022064-B2 | Phenylpentadienoyl derivatives and their use as PAR 1 antagonists | PIERRE FABRE MEDICAMENT (FR) | 2011-09-20 | — | — | US | claimed |
| EP-2046748-B1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PF MEDICAMENT (FR) | 2011-03-02 | — | — | EP | claimed |
| US-20100003260-A1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-07 | — | — | US | claimed |
| EP-2046748-A1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | Pierre Fabre Medicament (FR) | 2009-04-15 | — | — | EP | claimed |
| WO-2007147822-A1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2007-12-27 | — | — | WO | claimed |
| EP-2046748-B1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PF MEDICAMENT (FR) | 2011-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003260-A1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | F2R, F2RL1, FPR1 | LMNA 2919/4885RAB9A 2764/4885MEN1 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.